BeOne Medicines AG has recently released its 10-K report, revealing its financial performance and key developments. The company, based in Basel, Switzerland, is an oncology firm engaged in discovering and developing various treatments for cancer patients globally. Its commercial stage products include BRUKINSA, TEVIMBRA, and PARTRUVIX, while its clinical stage products comprise Sonrotoclax BGB-11417, BGB-16673, Ociperlimab (BGB-A1217), and several others. The company has agreements with Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeOne Medicines AG was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. It was founded in 2010.
In the 10-K report, BeOne Medicines AG reported total global revenues of $1.5 billion and $5.3 billion in the fourth quarter and full year of 2025, representing increases of 32.8% and 40.2% compared to the prior year periods, respectively. Global BRUKINSA revenues were $1.1 billion and $3.9 billion for the fourth quarter and full year 2025, marking increases of 38.4% and 48.6% compared to the prior year periods. The company reported GAAP diluted earnings per American Depositary Share (“ADS”) of $0.58 and $2.53 for the fourth quarter and full year, and non-GAAP diluted earnings per ADS of $1.95 and $8.09 for the same periods.
Recent business developments highlighted in the report include new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, receiving the first approval for adult patients with relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, and the U.S. Food and Drug Administration accepting and granting Priority Review to a New Drug Application for sonrotoclax. Additionally, positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab) were announced.
The report also detailed the company's financial performance, with total revenue increasing by $1.5 billion to $5.3 billion for the year ended December 31, 2025, primarily due to increased sales of BRUKINSA, TEVIMBRA, and in-licensed products from Amgen. Gross margin on global product sales increased to $4.6 billion, or 87.3% as a percentage of sales, for the year ended December 31, 2025, compared to $3.2 billion, or 84.3% as a percentage of sales, for the year ended December 31, 2024.
Research and development expenses increased by $192.6 million, or 9.9%, to $2.1 billion for the year ended December 31, 2025, primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage, including sonrotoclax, as well as higher Amgen co-development expenses.
Following these announcements, the company's shares moved -0.03%, and are now trading at a price of $338.19. For the full picture, make sure to review BeOne Medicines's 10-K report.
